Tags

Type your tag names separated by a space and hit enter

Candidate drugs against SARS-CoV-2 and COVID-19.
Pharmacol Res. 2020 07; 157:104859.PR

Abstract

Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future. Because a vaccine against the virus will not be available in the near future, we herein try to offer a pharmacological strategy to combat the virus. There exists a number of candidate drugs that may inhibit infection with and replication of SARS-CoV-2. Such drugs comprise inhibitors of TMPRSS2 serine protease and inhibitors of angiotensin-converting enzyme 2 (ACE2). Blockade of ACE2, the host cell receptor for the S protein of SARS-CoV-2 and inhibition of TMPRSS2, which is required for S protein priming may prevent cell entry of SARS-CoV-2. Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochemicals available to date may limit spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic.

Authors+Show Affiliations

Integrative Cancer Consulting, Aptos, CA, USA.Center and Network for Targeted Oncology, Muehlackerweg 8, D-69239, Heidelberg, Germany.Center and Network for Targeted Oncology, Muehlackerweg 8, D-69239, Heidelberg, Germany.Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität, Tübingen and Tuebingen Center for Academic Drug Discovery, Auf Der Morgenstelle 8, 72076, Tuebingen, Germany.Institute of Immunology, University of Heidelberg, Im Neuenheimer Feld 305, D-69120, Heidelberg, Germany. Electronic address: prof.naujokat@gmx.de.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32360480

Citation

McKee, Dwight L., et al. "Candidate Drugs Against SARS-CoV-2 and COVID-19." Pharmacological Research, vol. 157, 2020, p. 104859.
McKee DL, Sternberg A, Stange U, et al. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020;157:104859.
McKee, D. L., Sternberg, A., Stange, U., Laufer, S., & Naujokat, C. (2020). Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacological Research, 157, 104859. https://doi.org/10.1016/j.phrs.2020.104859
McKee DL, et al. Candidate Drugs Against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020;157:104859. PubMed PMID: 32360480.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Candidate drugs against SARS-CoV-2 and COVID-19. AU - McKee,Dwight L, AU - Sternberg,Ariane, AU - Stange,Ulrike, AU - Laufer,Stefan, AU - Naujokat,Cord, Y1 - 2020/04/29/ PY - 2020/03/27/received PY - 2020/04/20/revised PY - 2020/04/22/accepted PY - 2020/5/4/pubmed PY - 2020/5/4/medline PY - 2020/5/4/entrez KW - Arbidol KW - COVID-19 KW - Camostat KW - Chloroquine KW - Drugs KW - Favipiravir KW - Lopinavir KW - Phytochemicals KW - Remdesivir KW - Ritonavir KW - SARS-CoV-2 SP - 104859 EP - 104859 JF - Pharmacological research JO - Pharmacol. Res. VL - 157 N2 - Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future. Because a vaccine against the virus will not be available in the near future, we herein try to offer a pharmacological strategy to combat the virus. There exists a number of candidate drugs that may inhibit infection with and replication of SARS-CoV-2. Such drugs comprise inhibitors of TMPRSS2 serine protease and inhibitors of angiotensin-converting enzyme 2 (ACE2). Blockade of ACE2, the host cell receptor for the S protein of SARS-CoV-2 and inhibition of TMPRSS2, which is required for S protein priming may prevent cell entry of SARS-CoV-2. Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochemicals available to date may limit spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic. SN - 1096-1186 UR - https://www.unboundmedicine.com/medline/citation/32360480/Candidate_drugs_against_SARS_CoV_2_and_COVID_19_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1043-6618(20)31167-1 DB - PRIME DP - Unbound Medicine ER -